Published in
Wiley, Arthritis and Rheumatology, 4(74), p. 733-734, 2022
DOI: 10.1002/art.41993
Links
Tools
Additional points to consider before incorporating the Food and Drug Administration‐approved therapies for systemic sclerosis‐associated interstitial lung disease
Journal article published in 2021 by
Markus Bredemeier 
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 